Back to Search
Start Over
Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas. The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
- Source :
- Sarcoma, Vol 4, Iss 1-2, Pp 31-35 (2000)
- Publication Year :
- 2000
- Publisher :
- Wiley, 2000.
-
Abstract
- Purpose. Doxorubicin (dox) still appears to be one of the most active drugs in the treatment of soft tissue sarcomas. However, treatment duration is limited due to cumulative cardiotoxicity. A number of small studies from single institutions have suggested activity of other analogues. In two studies the EORTC STBSG tested whether epirubicin (epi) is an alternative to standard dose dox in the treatment of chemonaive patients with advanced soft tissue sarcoma. The present report gives the final results of these studies.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 1357714X and 13691643
- Volume :
- 4
- Issue :
- 1-2
- Database :
- Directory of Open Access Journals
- Journal :
- Sarcoma
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.877a787ac2b44e61b19b98367642c66c
- Document Type :
- article
- Full Text :
- https://doi.org/10.1155/S1357714X00000062